Donald Trump’s administration announced Tuesday that 15 new drugs, including drugs for cancer, diabetes, HIV and arthritis, have been selected for the Medicare Drug Price Negotiation Program, a move that could save Americans billions of dollars when revised prices take effect.
“For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs,” said Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz.
“Under President Trump’s leadership, CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and ensure the system works for patients — not special interests. This approach is delivering real savings while strengthening program-wide accountability,” he added.
Tuesday’s announcement is part of the Trump administration’s push to lower prescription drug costs for Americans, with new prices for the current list of drugs expected to take effect on Jan. 1, 2028, following this year’s negotiations.
Two phases have already been completed, with the negotiated prices for the first 10 drugs coming into effect on January 1, 2026. While the prices of the 15 drugs selected in the second phase are also being negotiated, the price change will take effect from January 1, 2027.
Which drugs were selected for price negotiations in the third phase?
Fifteen drugs have been selected for the third list, which will be negotiated in 2026.
The selected drugs for the third cycle of negotiations are:
CMS said that between November 1, 2024 and October 31, 2025, up to 1,777,000 people with Medicare Part B and/or Part D coverage took the drugs considered for price negotiation in this current cycle.
CMS also reported that select drugs accounted for a whopping $27 billion in Medicare Part B and Part D spending in the above period, about 6% of total spending under those plans.
The table below shows the drugs mentioned, the number of users and the corresponding expenses.
In addition, the diabetes treatment Tradjenta was also selected for price renegotiation.
Drug Price Negotiation Timeline
After CMS announced the names of the 15 drugs for the third cycle, it also announced the timeline that this round of negotiations will follow.
